ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SIM0610

A development code. Also written as “SIM0610 for Injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Simcere Pharmaceutical Group.

Furthest: phase 1, since Dec 24, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group11 open or runningphase 1since Dec 24, 2025Dec 24, 2025Dec 2027phase 1 · NCT07348211

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 24, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07348211 · 260 planned · China

Ahead

  1. Dec 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07348211

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07348211Carcinoma, Non-Small-Cell Lung · China1RecruitingDec 2027260

How it is read

Names in the registry

  • “SIM0610 for Injection”, 2 entries

Codes read as this program: SIM0610.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.